News for AC Immune SA (ACIU)

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PDâ„¢ 2025 AC Immune to host symposium highlighting the compa

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

**media[556679]**

AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 ”“ AC Immune SA ( ACIU), a clinical-stage biopharmaceutical com

Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.

The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ACI-7104.056 in the treatment of early Parkinson’s disease.

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling by more than 150 points on Thursday. The Dow traded down 0.38% to 43,790.8...

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Thursday. Shares of Hillenbrand, Inc. HI rose sharply in today's session follo...

**media[464664]**

**media[456652]**

AC Immune SA (ACIU) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue is $1.71 million, and the earnings are ex

Shares of Granite Point Mortgage Trust Inc. GPMT rose sharply in today's pre-market trading after the company announced a third-quarter common and preferred sto...

AC Immune receives a milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for progress in phase 2b ReTain trial.

AC Immune SA (ACIU), a clinical-stage biopharmaceutical company, Tuesday said it will receive the second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals, Inc.

Maryland-based biotechnology company Gain Therapeutics, Inc. (GANX) is down over 27 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Loading... Loading... Shares of SentinelOne, Inc. S shares fell sharply during Friday's session after the company posted mixed first-quarter results. Sentinel...

Morning Reads